THE CHALLENGE

Up to 88% of immunotherapies fail after Phase I trials

Despite recent clinical successes, the path to approval remains steep for immuno-oncology candidates. Immunotherapies exhibit an overall likelihood of approval of 12.4%, significantly higher than other oncology drugs (5.3%), but still reflect a high failure rate. Most notably, Phase II is the biggest hurdle, with only 28.9% of candidates progressing due to insufficient efficacy signals.

These challenges are amplified by the limitations of conventional preclinical models, which lack patient-specific tumor architecture and fail to simulate complex immune-tumor interactions. As a result, promising therapies often stumble in clinical phases, leading to costly attrition and missed therapeutic opportunities.

OUR SOLUTION

Patient-derived organoid co-cultures for immunotherapy

HUB’s Immuno-oncology offering combines patient-derived organoids derived from a broad panel of cancer indications with T cells to mimic elements of the tumor-immune microenvironment in vitro. Our platform enables robust testing of T cell engagers, cytokine-based therapies, small molecule immunomodulators, bispecific antibodies, and CAR T-cells.

Non-autologous co-cultures

Scalable evaluation of immune-based therapies across diverse tumors

Non-autologous co-cultures pair healthy donor immune cells with tumor organoids from multiple patients. This approach enables the evaluation of immune-modulating agents across a broad range of tumor types and patient profiles.

speak to an expert

See the system in action

PBMCs infiltrate and eliminate a patient-derived tumor organoid


Blue: tumor organoid | Green: caspase activation (apoptosis) | Red: PBMCs

Autologous co-cultures

Immune-tumor interactions in a patient-specific context

Autologous co-cultures combine patient-derived tumor organoids with matched immune cells—such as PBMCs or TILs—from the same individual. This format captures patient-specific immune recognition, antigen presentation, and tumor resistance mechanisms.

speak to an expert

SUCCESS STORY

How our client used basket trials in-a-dish for tumor indication selection

Learn from two case studies demonstrating how organoid-based T cell co-cultures were used to test efficacy and identify oncological indications prior to clinical trials.

read now

Get in touch

Discover the transformative potential of our technology with a free consultation with an expert
X

Have any questions?

contact us